Literature DB >> 16176722

Evaluating whole genome amplification via multiply-primed rolling circle amplification for SNP genotyping of samples with low DNA yield.

Kaisa Silander1, Kati Komulainen, Pekka Ellonen, Minttu Jussila, Mervi Alanne, Minna Levander, Päivi Tainola, Kari Kuulasmaa, Veikko Salomaa, Markus Perola, Leena Peltonen, Janna Saarela.   

Abstract

The amount of available DNA is often a limiting factor in pursuing genetic analyses of large-scale population cohorts. An association between higher DNA yield from blood and several phenotypes associated with inflammatory states has recently been demonstrated, suggesting that exclusion of samples with very low DNA yield may lead to biased results in statistical analyses. Whole genome amplification (WGA) could present a solution to the DNA concentration-dependent sample selection. The aim was to thoroughly assess WGA for samples with low DNA yield, using the multiply-primed rolling circle amplification method. Fifty-nine samples were selected with the lowest DNA yield (less than 7.5 microg) among 799 samples obtained for one population cohort. The genotypes obtained from two replicate WGA samples and the original genomic DNA were compared by typing 24 single nucleotide polymorphisms (SNPs). Multiple genotype discrepancies were identified for 13 of the 59 samples. The largest portion of discrepancies was due to allele dropout in heterozygous genotypes in WGA samples. Pooling the WGA DNA replicates prior to genotyping markedly improved genotyping reproducibility for the samples, with only 7 discrepancies identified in 4 samples. The nature of discrepancies was mostly homozygote genotypes in the genomic DNA and heterozygote genotypes in the WGA sample, suggesting possible allele dropout in the genomic DNA sample due to very low amounts of DNA template. Thus, WGA is applicable for low DNA yield samples, especially if using pooled WGA samples. A higher rate of genotyping errors requires that increased attention be paid to genotyping quality control, and caution when interpreting results.

Mesh:

Substances:

Year:  2005        PMID: 16176722     DOI: 10.1375/1832427054936664

Source DB:  PubMed          Journal:  Twin Res Hum Genet        ISSN: 1832-4274            Impact factor:   1.587


  10 in total

1.  Allelic variants of IL1R1 gene associate with severe hand osteoarthritis.

Authors:  Annu Näkki; Sanna T Kouhia; Janna Saarela; Arsi Harilainen; Kaj Tallroth; Tapio Videman; Michele C Battié; Jaakko Kaprio; Leena Peltonen; Urho M Kujala
Journal:  BMC Med Genet       Date:  2010-03-30       Impact factor: 2.103

2.  Use of a genetic isolate to identify rare disease variants: C7 on 5p associated with MS.

Authors:  Suvi P Kallio; Eveliina Jakkula; Shaun Purcell; Minna Suvela; Keijo Koivisto; Pentti J Tienari; Irina Elovaara; Tuula Pirttilä; Mauri Reunanen; Denis Bronnikov; Markku Viander; Seppo Meri; Jan Hillert; Frida Lundmark; Hanne F Harbo; Aslaug R Lorentzen; Philip L De Jager; Mark J Daly; David A Hafler; Aarno Palotie; Leena Peltonen; Janna Saarela
Journal:  Hum Mol Genet       Date:  2009-02-16       Impact factor: 6.150

3.  The impact of newly identified loci on coronary heart disease, stroke and total mortality in the MORGAM prospective cohorts.

Authors:  Juha Karvanen; Kaisa Silander; Frank Kee; Laurence Tiret; Veikko Salomaa; Kari Kuulasmaa; Per-Gunnar Wiklund; Jarmo Virtamo; Olli Saarela; Claire Perret; Markus Perola; Leena Peltonen; Francois Cambien; Jeanette Erdmann; Nilesh J Samani; Heribert Schunkert; Alun Evans
Journal:  Genet Epidemiol       Date:  2009-04       Impact factor: 2.135

4.  Variation in the selenoprotein S gene locus is associated with coronary heart disease and ischemic stroke in two independent Finnish cohorts.

Authors:  Mervi Alanne; Kati Kristiansson; Kirsi Auro; Kaisa Silander; Kari Kuulasmaa; Leena Peltonen; Veikko Salomaa; Markus Perola
Journal:  Hum Genet       Date:  2007-07-20       Impact factor: 4.132

5.  Finding disease candidate genes by liquid association.

Authors:  Ker-Chau Li; Aarno Palotie; Shinsheng Yuan; Denis Bronnikov; Daniel Chen; Xuelian Wei; Oi-Wa Choi; Janna Saarela; Leena Peltonen
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

6.  Risk alleles of USF1 gene predict cardiovascular disease of women in two prospective studies.

Authors:  Kati Komulainen; Mervi Alanne; Kirsi Auro; Riika Kilpikari; Päivi Pajukanta; Janna Saarela; Pekka Ellonen; Kaisa Salminen; Sangita Kulathinal; Kari Kuulasmaa; Kaisa Silander; Veikko Salomaa; Markus Perola; Leena Peltonen
Journal:  PLoS Genet       Date:  2006-05-12       Impact factor: 5.917

7.  Combined effects of thrombosis pathway gene variants predict cardiovascular events.

Authors:  Kirsi Auro; Mervi Alanne; Kati Kristiansson; Kaisa Silander; Kari Kuulasmaa; Veikko Salomaa; Leena Peltonen; Markus Perola
Journal:  PLoS Genet       Date:  2007-06-07       Impact factor: 5.917

8.  Association of a nonsynonymous variant of DAOA with visuospatial ability in a bipolar family sample.

Authors:  Pia Soronen; Kaisa Silander; Mervi Antila; Outi M Palo; Annamari Tuulio-Henriksson; Tuula Kieseppä; Pekka Ellonen; Juho Wedenoja; Joni A Turunen; Olli P H Pietiläinen; William Hennah; Jouko Lönnqvist; Leena Peltonen; Timo Partonen; Tiina Paunio
Journal:  Biol Psychiatry       Date:  2008-05-07       Impact factor: 13.382

9.  An association analysis of murine anxiety genes in humans implicates novel candidate genes for anxiety disorders.

Authors:  Jonas Donner; Sami Pirkola; Kaisa Silander; Laura Kananen; Joseph D Terwilliger; Jouko Lönnqvist; Leena Peltonen; Iiris Hovatta
Journal:  Biol Psychiatry       Date:  2008-07-17       Impact factor: 13.382

10.  Gender differences in genetic risk profiles for cardiovascular disease.

Authors:  Kaisa Silander; Mervi Alanne; Kati Kristiansson; Olli Saarela; Samuli Ripatti; Kirsi Auro; Juha Karvanen; Sangita Kulathinal; Matti Niemelä; Pekka Ellonen; Erkki Vartiainen; Pekka Jousilahti; Janna Saarela; Kari Kuulasmaa; Alun Evans; Markus Perola; Veikko Salomaa; Leena Peltonen
Journal:  PLoS One       Date:  2008-10-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.